---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-033366"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:58:33.940352+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3

## Summary
- One share of Series A Preferred sold to CEO Leonard Mazur for $100 with 1B votes, valid only on proposed authorized share increase from 16M to 250M common shares.
- Board amended bylaws reducing stockholder meeting quorum from majority to one-third to avoid adjournment risk.
- Series A has no conversion, dividend, or liquidation rights; redeemed for $100 automatically after vote results announced.
- Special meeting called; preliminary proxy filed for shareholder vote on the authorized share increase.

## SEC filing metadata
- accession: 0001213900-25-033366
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025033366/0001213900-25-033366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025033366/ea0238657-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-033366
- JSON: https://secwatch.observer/filing/0001213900-25-033366.json
- Plain text: https://secwatch.observer/filing/0001213900-25-033366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.